# BMT CTN Core - Fred Hutchinson Cancer Center

> **NIH NIH UG1** · FRED HUTCHINSON CANCER CENTER · 2024 · $264,000

## Abstract

PROJECT SUMMARY/ABSTRACT
Over the last 22 years, the BMT CTN has effectively addressed key issues in hematopoietic cell transplantation
(HCT), including donor selection, choice of preparative regimens, prevention of post-transplant infection,
prevention and treatment of graft-versus-host disease, prevention of relapse, the role of transplant vs. non-
transplant therapy, and indications for HCT in the treatment of specific diseases, through the conduct of 61
clinical trials. The Fred Hutch Program has played an important role in the success of the BMT CTN since its
inception, serving as one of its Core Clinical Centers. There are many features of the Fred Hutch Program that
enhance its value as a Core Clinical Center. (1) The volume of clinical activity allows us to successfully recruit
and enroll patients on BMT CTN clinical trials, including patients with rare diseases. The Hutch’s performance in
reaching its BMT CTN accrual targets over the last four years has been rated by the BMT CTN as “outstanding.”
(2) Our extensive experience with HCT and adoptive cellular therapy provides outstanding clinical outcomes,
and we exceeded the 95% confidence limits for survival as calculated by the center-specific outcomes analysis
of the Center for International Blood and Marrow Transplant Research (CIBMTR) in 2018 and 2022. (3) The
faculty of the Fred Hutch Program includes a large number of investigators, all focused on various aspects of
HCT and cellular therapy. The breadth and depth of this group helps ensure that we will continue to provide
important scientific contributions to the network. Since 2018, our group has been rated as “outstanding” by the
BMT CTN for our scientific and administrative efforts. (4) The Fred Hutch has extensive experience with novel
cell therapies including stem cell expansion, genetic engineering of T cells, and correction of inborn errors, which
are areas of specific interest noted by the NHLBI and the NCI. (5) Our proposed phase 3 clinical trial of
preemptive treatment for chronic GVHD fulfills one of the recommendations of the 2020 NIH Chronic GVHD
Consensus Conference. (6) The faculty of the Fred Hutch have enthusiastically collaborated with other members
of the BMT CTN to help achieve the network’s research goals over the past funding periods with an overall rating
of outstanding from 2018-2022. We remain committed to the Network’s success.

## Key facts

- **NIH application ID:** 10940322
- **Project number:** 2UG1HL069246-25
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** STEPHANIE J LEE
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $264,000
- **Award type:** 2
- **Project period:** 2002-06-05 → 2031-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10940322

## Citation

> US National Institutes of Health, RePORTER application 10940322, BMT CTN Core - Fred Hutchinson Cancer Center (2UG1HL069246-25). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10940322. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*